References
- Chow E, Harris K, Fan G, et al (2007). Palliative radiotherapy trials for bone metastases: A systematic review. J Clin Oncol, 25, 1423-36. https://doi.org/10.1200/JCO.2006.09.5281
- De Bari B, Alongi F, Mortellaro G, et al (2015). Spinal metastases: Is stereotactic body radiation therapy supported by evidences? Crit Rev Oncol Hematol. [Epub ahead of print]
- Germano IM, Carai A, Pawha P, et al (2015). Clinical outcome of vertebral compression fracture after single fraction spine radiosurgery for spinalmetastases. Clin Exp Metastasis. 2015 Nov 17. [Epub ahead of print]
- Gerszten PC, Burton SA, Ozhasoglu C, et al (2007). Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976), 32, 193-9. https://doi.org/10.1097/01.brs.0000251863.76595.a2
- Mantel F, Glatz S, Toussaint A, et al (2014). Long-term safety and efficacy of fractionated stereotactic body radiation therapy for spinal metastases. Strahlenther Onkol, 90, 1141-8.
- Moussazadeh N, Lis E, Katsoulakis E, et al (2015). Five-year outcomes of high-dose single-fraction spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys, 93, 361-7. https://doi.org/10.1016/j.ijrobp.2015.05.035
- Murai T, Murata R, Manabe Y, et al (2014). Intensity modulated stereotactic body radiation therapy for single or multiple vertebral metastases with spinal cord compression. Pract Radiat Oncol, 4, 231-7. https://doi.org/10.1016/j.prro.2014.02.005
- Park HJ, Kim HJ, Won JH, et al (2015). Stereotactic body radiotherapy (SBRT) for spinal metastases: who will benefit the most from SBRT? Technol Cancer Res Treat, 14, 159-67. https://doi.org/10.7785/tcrt.2012.500411
- Price P, Hoskin PJ, Easton D, et al (1988). Low dose single fraction radiotherapy in the treatment of metastatic bone pain: A pilot study. Radiother Oncol, 12, 297-300. https://doi.org/10.1016/0167-8140(88)90019-9
- Thibault I, Campbell M, Tseng CL, et al (2015). Salvage stereotactic body radiotherapy (SBRT) following in-field failure of initial SBRT for spinal metastases. Int J Radiat Oncol Biol Phys, 93, 353-60. https://doi.org/10.1016/j.ijrobp.2015.03.029
Cited by
- Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma vol.19, pp.1, 2019, https://doi.org/10.1186/s12885-019-5266-4